CTX.TO (Mkap C$ 7.7 M) 1x FDA approved /2x Phase 3 und weitere Produkte am Markt (Seite 9)
eröffnet am 10.01.18 20:30:45 von
neuester Beitrag 17.03.24 19:06:07 von
neuester Beitrag 17.03.24 19:06:07 von
Beiträge: 157
ID: 1.271.450
ID: 1.271.450
Aufrufe heute: 0
Gesamt: 23.361
Gesamt: 23.361
Aktive User: 0
ISIN: CA2258471028 · WKN: A2AD5R · Symbol: CTX
0,4300
CAD
-2,27 %
-0,0100 CAD
Letzter Kurs 25.04.24 Toronto
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4137 | +44,53 | |
| 0,7500 | +36,36 | |
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 20,000 | -28,06 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit
https://www.prnewswire.com/news-releases/crescita-therapeuti…
https://www.prnewswire.com/news-releases/crescita-therapeuti…
Antwort auf Beitrag Nr.: 60.423.183 von Palawanobi am 25.04.19 16:17:58https://www.prnewswire.com/news-releases/crescita-therapeuti…
Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement with Cantabria Labs for €2.5M Upfront After Reacquiring Rest...
https://de.advfn.com/p.php?pid=nmona&article=79766642
https://de.advfn.com/p.php?pid=nmona&article=79766642
Antwort auf Beitrag Nr.: 60.162.033 von Jim_Panse am 21.03.19 15:02:41Und das Ganze bei einer Marketcap von gerade mal 13,5 Mio CAD!
Antwort auf Beitrag Nr.: 60.161.592 von Palawanobi am 21.03.19 14:21:16"Our Q4 results were extremely positive as we reported record revenues and Adjusted EBITDA, fueled not only by milestone and royalty revenue but by our delivery of significant operational improvements in our business," said Serge Verreault, President and CEO of Crescita.
Financial Highlights
Q4-F2018
Revenue of $6.2 million, up $3.8 million or 163.3% versus Q4-F2017;
Revenue includes $1.4 million of royalties on the U.S. net sales of Pliaglis and $2.0 million in sales and development milestones;
Adjusted EBITDA1 of $1.8 million, up $3.8 million versus Q4-F2017;
Ending cash position of $8.6 million versus $7.0 million as at December 31, 2017;
F2018
Revenue of $16.6 million, up $4.6 million or 38.4% versus F2017;
Revenue includes $4.1 million of royalties on the U.S. net sales of Pliaglis and $3.3 million in sales and development milestones;
Operating expenses of $16.7 million, down $1.6 million or 8.6% versus F2017;
Adjusted EBITDA1 of $1.5 million, an improvement of $5.9 million versus F2017;
Cash and Cash Equivalents
Total cash generated during the year was $1.6 million, resulting in an ending cash and cash equivalents balance of $8.6 million as at December 31, 2018, compared to $7.0 million at December 31, 2017. The year-end cash balance included $3.5 million in net proceeds from the Company's Rights Offering concluded in March of 2018.
Financial Highlights
Q4-F2018
Revenue of $6.2 million, up $3.8 million or 163.3% versus Q4-F2017;
Revenue includes $1.4 million of royalties on the U.S. net sales of Pliaglis and $2.0 million in sales and development milestones;
Adjusted EBITDA1 of $1.8 million, up $3.8 million versus Q4-F2017;
Ending cash position of $8.6 million versus $7.0 million as at December 31, 2017;
F2018
Revenue of $16.6 million, up $4.6 million or 38.4% versus F2017;
Revenue includes $4.1 million of royalties on the U.S. net sales of Pliaglis and $3.3 million in sales and development milestones;
Operating expenses of $16.7 million, down $1.6 million or 8.6% versus F2017;
Adjusted EBITDA1 of $1.5 million, an improvement of $5.9 million versus F2017;
Cash and Cash Equivalents
Total cash generated during the year was $1.6 million, resulting in an ending cash and cash equivalents balance of $8.6 million as at December 31, 2018, compared to $7.0 million at December 31, 2017. The year-end cash balance included $3.5 million in net proceeds from the Company's Rights Offering concluded in March of 2018.
Trading Spotlight
"Booom"
Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M
and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones
https://www.prnewswire.com/news-releases/crescita-therapeuti…
and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones
https://www.prnewswire.com/news-releases/crescita-therapeuti…
So langsam wird es spannend, die nächsten Zahlen stehen wohl bald an (Voraussichtlich ende März). Vielleicht können sie schon sagen, ob die "Not for Home Use" Label Restriction für Pliaglis einen positiven Effekt hat. Ansonsten konnten sie schon in Q3 2018 einen positiven Effekt erzielen, jedoch nur mit Hilfe teilweise einmaligen Milestones, der Trend ist jedoch ganz klar positiv! Hier nochmal die Highlights von Q3:
Key Q3-18 and Subsequent to Quarter-end Highlights
• Revenue of $4.5 million, including $1.1 million in royalty revenue on the net sales of Pliaglis and a $1.3
million (US$1.0 million) sales milestone, an increase of $1.7 million or 64.1% vs Q3-17;
• Operating expenses down $0.1 million versus Q3-17 and $1.5 million on a year-to-date basis;
• Adjusted EBITDA1 of $0.8 million, up $1.8 million versus Q3-17, and an improvement of $2.1 million on a
year-to-date basis;
• Total cash utilized during the quarter of $0.9 million, resulting in an ending cash and cash equivalents
balance of $8.2 million as at September 30, 2018, compared to $9.1 million in Q2-18;
• Reported favourable results from a skin permeation study using our patented technologies, MMPE™ and
DuraPeel™, demonstrating significantly increased transdermal permeation of Cannabidiol (“CBD”) over the
control formulation by up to 14- and 6-fold, respectively;
• Launched five product innovations on November 5 in our non-Rx business, leveraging our patented
MMPE™ technology and Ecobiotys®,2, a new award-winning prebiotic. Due to our expertise and product
development speed, Crescita is one of the very first companies worldwide to release a product formulation
using Ecobiotys®,2
Ps: Heute waren endlich mal akzeptable Stückmengen verfügbar und somit habe ich meine Anzahl ordenlich erhöht und warte nun gespannt auf die nächsten Monate :-) Sonst noch jemand dabei?
Key Q3-18 and Subsequent to Quarter-end Highlights
• Revenue of $4.5 million, including $1.1 million in royalty revenue on the net sales of Pliaglis and a $1.3
million (US$1.0 million) sales milestone, an increase of $1.7 million or 64.1% vs Q3-17;
• Operating expenses down $0.1 million versus Q3-17 and $1.5 million on a year-to-date basis;
• Adjusted EBITDA1 of $0.8 million, up $1.8 million versus Q3-17, and an improvement of $2.1 million on a
year-to-date basis;
• Total cash utilized during the quarter of $0.9 million, resulting in an ending cash and cash equivalents
balance of $8.2 million as at September 30, 2018, compared to $9.1 million in Q2-18;
• Reported favourable results from a skin permeation study using our patented technologies, MMPE™ and
DuraPeel™, demonstrating significantly increased transdermal permeation of Cannabidiol (“CBD”) over the
control formulation by up to 14- and 6-fold, respectively;
• Launched five product innovations on November 5 in our non-Rx business, leveraging our patented
MMPE™ technology and Ecobiotys®,2, a new award-winning prebiotic. Due to our expertise and product
development speed, Crescita is one of the very first companies worldwide to release a product formulation
using Ecobiotys®,2
Ps: Heute waren endlich mal akzeptable Stückmengen verfügbar und somit habe ich meine Anzahl ordenlich erhöht und warte nun gespannt auf die nächsten Monate :-) Sonst noch jemand dabei?
Und weiter geht die wilde Fahrt. Ask hängt aktuell bei 0,58 fest. Bin guter Dinge, dass hier vor Veröffentlichung der Zahlen noch das ein oder andere % drin ist...
Durchsuchen
